Skip to content

First-in-Human implantation for Novostia’s heart valve

Share this article

The Vaud-based startup, located at the Biopôle, successfully implanted its TRIFLO valve in a human.



Novostia, a pioneering medical technology company, proudly announces a significant milestone in its mission to revolutionize cardiovascular care. Last December, the company has successfully implanted its groundbreaking TRIFLO Heart Valve in a human patient for the first time. In fact, it marks a momentous achievement in the field of valve replacement. This FIH was performed in the context of a prospective, single-arm, exploratory clinical investigation to assess preliminary safety and collect performance and effectiveness data of the TRIFLO Heart Valve.


Motivated by better Patient care and well-being through breakthrough innovation

Novostia’s TRIFLO Heart Valve represents a cutting-edge advancement in cardiac technology. Its design revolutionise aortic heart valve replacement, offering unprecedented improvements in blood flow dynamics and product longevity. Significantly, it paves the way towards eliminating the need for lifelong anticoagulation therapy, a paradigmatic shift in the treatment of heart valve diseases. This breakthrough not only minimises the risks associated with prolonged anticoagulation but also addresses patient concerns like noise-induced discomfort, enhancing their quality of life. This milestone is a testament to Novostia’s commitment to innovation and its unwavering dedication to improving patient outcomes in the cardiovascular space.

The successful implantation of the TRIFLO Heart Valve is a significant step forward in aortic valve disease management. Seeing our patients recover fully and thrive post-surgery reinforces the valve’s potential to change the landscape of aortic valve treatment.“, said Prof. Kęstutis Ručinskas, who led the clinical investigation an implantation procedure.


Global Impact on Cardiovascular Health

Novostia’s TRIFLO Heart Valve is poised to bring about a quiet revolution in the treatment of aortic heart valve replacement. The company anticipates that patients around the world will soon benefit from this disruptive technology. This will offer a new level of hope and improved quality of life for those with aortic stenosis and/or regurgitation.


About Novostia

Novostia is a privately held medical device company incorporated in 2017 in Neuchâtel, Switzerland, developing an innovative artificial heart valve.



Source: press release